Pfizer buys China rights to Sciwind’s approved GLP-1 drug in metabolic push

Pfizer has recently gone shopping for investigational GLP-1 drugs in China to take them to the rest of the world. Now, the large drugmaker is going to China and staying there. The New York pharma ...